CLAIMS

1. A compound represented by the following formula:



[I]

wherein R represents an unsubstitued pyridyl, furyl, or thienyl group,

m represents an integer of 1 to 3,

G represents a β-D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolocarbazole ring are the 1- and 11-positions, or the 2- and 10-positions,

or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1, represented by the following formula:



[I-a]

wherein R and G are the same as defined in Claim 1,

or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 2, wherein R is a pyridine-4-yl group,

or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1, represented by the following formula:



[I -b]

wherein R and G are the same as defined in Claim 1,
or a pharmaceutically acceptable salt thereof.

5. An anti-tumor agent comprising, together with a pharmaceutically acceptable carrier or diluent, an effective amount of the compound according to Claim 1 or a pharmaceutically acceptable salt thereof, sufficient to exhibit antitumor activity

6. The anti-tumor agent according to Claim 5 which is used for the treatment of lung cancer.